Matinas BioPharma Holdings (MTNB) Non-Current Deffered Revenue (2017 - 2018)
Matinas BioPharma Holdings (MTNB) posted quarterly Non-Current Deffered Revenue of $512704.0 for Q4 2018, up 12.55% year-over-year from $455554.0 in Q4 2017, and up 2.17% quarter-over-quarter from $501816.0 in Q3 2018.
Matinas BioPharma Holdings (MTNB) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Non-Current Deffered Revenue for 2 consecutive years, with $512704.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue rose 12.55% year-over-year to $512704.0; the TTM figure through Dec 2018 stood at $512704.0 (up 12.55% YoY), while the FY2018 annual figure was $512704.0, up 12.55% from the prior year.
- Non-Current Deffered Revenue grew to $512704.0 in Q4 2018 per MTNB's latest filing, from $501816.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $512704.0 in Q4 2018 and bottomed at $455554.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 512,704.00 |
| Sep 30, 2018 | 501,816.00 |
| Jun 30, 2018 | 489,161.00 |
| Mar 31, 2018 | 472,480.00 |
| Dec 31, 2017 | 455,554.00 |